Possible medication errors with arsenic trioxide
- PDF / 169,504 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 45 Downloads / 235 Views
1
Possible medication errors with arsenic trioxide There may be a risk of medication errors following the introduction of a new formulation of arsenic trioxide [Trisenox], according to a Direct Healthcare Professional Communication from Teva Pharmaceuticals Ireland in association with the HPRA and EMA. Arsenic trioxide is indicated for some patients with acute promyelocytic leukaemia (APL). The currently available formula is a 1 mg/ml 10ml ampoule containing 10mg of arsenic trioxide. The new formula is a 2 mg/ml 6m vial containing 12mg of arsenic trioxide. Although each package has distinctive features, there may be confusion between the two products leading to medication errors. Administration of an overdose may enhance the known adverse events of arsenic trioxide, potentially with a fatal outcome. These include APL differentiation syndrome, hepatic toxicity, hyperleukocytosis, leukopenia, nephrotoxicity, QTc prolongation and thrombocytopenia. Administration of an underdose may reduce the clinical response, possibly resulting in cancer chemotherapy resistance. Healthcare professionals are advised to check carefully when calculating dilutions and infusion volumes, and to report any suspected adverse reactions. HPRA. Direct Healthcare Professional Communication - TRISENOX (arsenic trioxide) - Risk of medication errors due to the introduction of 2 mg/ml concentration. Internet Document : Oct 2020. Available from: URL: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---trisenox-(arsenic803516874 trioxide).pdf?sfvrsn=0
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
